BlueMountain Capital Management LLC lifted its stake in shares of Phibro Animal Health Corp (NASDAQ:PAHC) by 60.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 22,454 shares of the company’s stock after purchasing an additional 8,451 shares during the period. BlueMountain Capital Management LLC owned 0.06% of Phibro Animal Health worth $1,034,000 at the end of the most recent quarter.
Other hedge funds also recently modified their holdings of the company. Royal Bank of Canada boosted its holdings in Phibro Animal Health by 2,104.6% in the 1st quarter. Royal Bank of Canada now owns 3,814 shares of the company’s stock valued at $151,000 after purchasing an additional 3,641 shares during the period. Meeder Asset Management Inc. lifted its holdings in shares of Phibro Animal Health by 149.2% during the 2nd quarter. Meeder Asset Management Inc. now owns 4,470 shares of the company’s stock worth $206,000 after acquiring an additional 2,676 shares during the last quarter. Piedmont Investment Advisors LLC bought a new stake in shares of Phibro Animal Health during the 2nd quarter worth $213,000. Highbridge Capital Management LLC bought a new stake in shares of Phibro Animal Health during the 1st quarter worth $214,000. Finally, Janus Henderson Group PLC bought a new stake in shares of Phibro Animal Health during the 2nd quarter worth $222,000. Institutional investors own 49.19% of the company’s stock.
In other news, insider Jack Bendheim sold 30,000 shares of Phibro Animal Health stock in a transaction dated Wednesday, July 11th. The shares were sold at an average price of $46.89, for a total transaction of $1,406,700.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Bfi Co., Llc sold 10,000 shares of Phibro Animal Health stock in a transaction dated Wednesday, July 11th. The shares were sold at an average price of $46.89, for a total transaction of $468,900.00. Following the sale, the insider now directly owns 60,000 shares in the company, valued at approximately $2,813,400. The disclosure for this sale can be found here. Insiders have sold a total of 283,960 shares of company stock worth $13,823,627 in the last ninety days. Insiders own 50.29% of the company’s stock.
NASDAQ:PAHC traded down $0.84 during trading hours on Friday, reaching $43.39. The company’s stock had a trading volume of 133,134 shares, compared to its average volume of 112,387. Phibro Animal Health Corp has a 1 year low of $32.05 and a 1 year high of $54.62. The stock has a market cap of $1.73 billion, a PE ratio of 24.94, a PEG ratio of 2.48 and a beta of 0.91. The company has a quick ratio of 1.66, a current ratio of 2.90 and a debt-to-equity ratio of 1.62.
Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings data on Monday, August 27th. The company reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. The firm had revenue of $211.80 million for the quarter, compared to analysts’ expectations of $209.27 million. Phibro Animal Health had a net margin of 7.90% and a return on equity of 39.81%. The company’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.39 earnings per share. Sell-side analysts anticipate that Phibro Animal Health Corp will post 1.8 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Wednesday, September 26th. Stockholders of record on Wednesday, September 5th were paid a dividend of $0.10 per share. This represents a $0.40 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date of this dividend was Tuesday, September 4th. Phibro Animal Health’s payout ratio is 22.99%.
A number of analysts have recently issued reports on the stock. BidaskClub raised shares of Phibro Animal Health from a “hold” rating to a “buy” rating in a report on Wednesday, August 8th. Morgan Stanley lifted their price objective on shares of Phibro Animal Health from $36.00 to $46.00 and gave the stock an “underweight” rating in a report on Wednesday, August 29th. Zacks Investment Research downgraded shares of Phibro Animal Health from a “hold” rating to a “sell” rating in a report on Wednesday, August 29th. Finally, Barclays lifted their target price on shares of Phibro Animal Health from $31.00 to $33.00 and gave the stock an “underweight” rating in a research report on Thursday, July 5th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. Phibro Animal Health currently has a consensus rating of “Hold” and a consensus target price of $43.20.
About Phibro Animal Health
Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.
See Also: Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.